Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immunic, Inc. stock logo
IMUX
Immunic
$7.40
-1.6%
$8.29
$5.06
▼
$17.43
$119.42M1.48241,307 shs390,616 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.17
-1.7%
$1.35
$0.85
▼
$1.93
$29.86M1.82486,334 shs160,039 shs
PolyPid Ltd. stock logo
PYPD
PolyPid
$6.55
-0.2%
$5.46
$3.50
▼
$7.25
$125.19M1.43217,189 shs453,565 shs
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
$1.36
$2.34
$1.28
▼
$6.95
$97.47M1.911.40 million shs1.45 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immunic, Inc. stock logo
IMUX
Immunic
+2.59%-7.39%+7.58%-53.29%-1.05%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
+2.59%-13.77%-8.46%-9.16%-13.77%
PolyPid Ltd. stock logo
PYPD
PolyPid
+0.31%-0.61%+34.43%+29.13%+80.22%
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
-8.72%-28.04%-40.87%-64.58%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immunic, Inc. stock logo
IMUX
Immunic
$7.40
-1.6%
$8.29
$5.06
▼
$17.43
$119.42M1.48241,307 shs390,616 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.17
-1.7%
$1.35
$0.85
▼
$1.93
$29.86M1.82486,334 shs160,039 shs
PolyPid Ltd. stock logo
PYPD
PolyPid
$6.55
-0.2%
$5.46
$3.50
▼
$7.25
$125.19M1.43217,189 shs453,565 shs
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
$1.36
$2.34
$1.28
▼
$6.95
$97.47M1.911.40 million shs1.45 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immunic, Inc. stock logo
IMUX
Immunic
+2.59%-7.39%+7.58%-53.29%-1.05%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
+2.59%-13.77%-8.46%-9.16%-13.77%
PolyPid Ltd. stock logo
PYPD
PolyPid
+0.31%-0.61%+34.43%+29.13%+80.22%
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
-8.72%-28.04%-40.87%-64.58%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immunic, Inc. stock logo
IMUX
Immunic
2.85
Moderate Buy$32.71342.08% Upside
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.00
Buy$6.00412.82% Upside
PolyPid Ltd. stock logo
PYPD
PolyPid
2.50
Moderate Buy$11.6778.12% Upside
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
2.80
Moderate Buy$8.29509.24% Upside

Current Analyst Ratings Breakdown

Latest NNVC, PYPD, IMUX, and ZNTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Immunic, Inc. stock logo
IMUX
Immunic
Reiterated RatingBuy$3.00
11/12/2026
PolyPid Ltd. stock logo
PYPD
PolyPid
Reiterated RatingBuy$13.00
11/10/2026
Immunic, Inc. stock logo
IMUX
Immunic
DowngradeStrong-Buy ➝ Hold
11/10/2026
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
UpgradeNeutral ➝ Outperform$5.00 ➝ $6.00
10/27/2026
PolyPid Ltd. stock logo
PYPD
PolyPid
Initiated CoverageOutperform$10.00
10/23/2026
Immunic, Inc. stock logo
IMUX
Immunic
Initiated CoverageOverweight
10/21/2026
Immunic, Inc. stock logo
IMUX
Immunic
UpgradeHold ➝ Strong-Buy
10/19/2026
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
Reiterated RatingBuy$10.00
10/14/2026
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
UpgradeHold ➝ Strong-Buy
10/5/2026
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
Initiated CoverageMarket Perform ➝ Outperform$4.00 ➝ $8.00
10/2/2026
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
Reiterated RatingSell (D-)
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/A$6.58 per shareN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
PolyPid Ltd. stock logo
PYPD
PolyPid
N/AN/AN/AN/A$0.20 per shareN/A
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
$67.43M1.45N/AN/A$2.86 per share0.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immunic, Inc. stock logo
IMUX
Immunic
-$97.17M-$4.07N/AN/AN/AN/A-136.26%-100.75%N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.53N/AN/AN/AN/A-87.90%-78.69%N/A
PolyPid Ltd. stock logo
PYPD
PolyPid
-$34.17M-$1.35N/AN/AN/AN/A-410.49%-123.13%N/A
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
-$137.06M-$1.92N/AN/AN/AN/A-75.82%-55.15%N/A

Latest NNVC, PYPD, IMUX, and ZNTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Immunic, Inc. stock logo
IMUX
Immunic
-$0.7852-$0.99-$0.2048-$0.99N/AN/A
11/11/2026Q3 2026
PolyPid Ltd. stock logo
PYPD
PolyPid
$0.9130-$0.24-$1.1530-$0.24$30.00 million$30.00 million
11/9/2026Q3 2026
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
-$0.5423-$0.34+$0.2023-$0.34N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
PolyPid Ltd. stock logo
PYPD
PolyPid
N/AN/AN/AN/AN/A
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immunic, Inc. stock logo
IMUX
Immunic
N/A
4.28
5.05
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47
PolyPid Ltd. stock logo
PYPD
PolyPid
N/A
5.94
1.35
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
N/A
7.33
7.33

Institutional Ownership

CompanyInstitutional Ownership
Immunic, Inc. stock logo
IMUX
Immunic
51.82%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%
PolyPid Ltd. stock logo
PYPD
PolyPid
26.47%
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Immunic, Inc. stock logo
IMUX
Immunic
5.49%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
2.80%
PolyPid Ltd. stock logo
PYPD
PolyPid
24.70%
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
3.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immunic, Inc. stock logo
IMUX
Immunic
9515.88 million15.01 millionOptionable
NanoViricides, Inc. stock logo
NNVC
NanoViricides
725.53 million14.92 millionOptionable
PolyPid Ltd. stock logo
PYPD
PolyPid
7219.08 million14.37 millionOptionable
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
10671.67 million68.95 millionOptionable

Recent News About These Companies

HC Wainwright Has Positive Outlook for ZNTL FY2026 Earnings
Morgan Stanley Remains a Hold on Zentalis Pharmaceuticals (ZNTL)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Immunic stock logo

Immunic NASDAQ:IMUX

$7.40 -0.12 (-1.60%)
Closing price 03:59 PM Eastern
Extended Trading
$7.47 +0.07 (+0.95%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.17 -0.02 (-1.68%)
Closing price 04:00 PM Eastern
Extended Trading
$1.19 +0.02 (+1.71%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

PolyPid stock logo

PolyPid NASDAQ:PYPD

$6.55 -0.01 (-0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$6.62 +0.07 (+1.05%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Zentalis Pharmaceuticals stock logo

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.36 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.38 +0.02 (+1.84%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.